Journal of Clinical Medicine (Sep 2022)

Combining Awake Anesthesia with Minimal Invasive Surgery Optimizes Intraoperative Surgical Spinal Cord Stimulation Lead Placement

  • Philippe Rigoard,
  • Amine Ounajim,
  • Lisa Goudman,
  • Chantal Wood,
  • Manuel Roulaud,
  • Philippe Page,
  • Bertille Lorgeoux,
  • Sandrine Baron,
  • Kevin Nivole,
  • Mathilde Many,
  • Emmanuel Cuny,
  • Jimmy Voirin,
  • Denys Fontaine,
  • Sylvie Raoul,
  • Patrick Mertens,
  • Philippe Peruzzi,
  • François Caire,
  • Nadia Buisset,
  • Romain David,
  • Maarten Moens,
  • Maxime Billot

DOI
https://doi.org/10.3390/jcm11195575
Journal volume & issue
Vol. 11, no. 19
p. 5575

Abstract

Read online

Spinal cord stimulation (SCS) is an effective and validated treatment to address chronic refractory neuropathic pain in persistent spinal pain syndrome-type 2 (PSPS-T2) patients. Surgical SCS lead placement is traditionally performed under general anesthesia due to its invasiveness. In parallel, recent works have suggested that awake anesthesia (AA), consisting of target controlled intra-venous anesthesia (TCIVA), could be an interesting tool to optimize lead anatomical placement using patient intra-operative feedback. We hypothesized that combining AA with minimal invasive surgery (MIS) could improve SCS outcomes. The goal of this study was to evaluate SCS lead performance (defined by the area of pain adequately covered by paraesthesia generated via SCS), using an intraoperative objective quantitative mapping tool, and secondarily, to assess pain relief, functional improvement and change in quality of life with a composite score. We analyzed data from a prospective multicenter study (ESTIMET) to compare the outcomes of 115 patients implanted with MIS under AA (MISAA group) or general anesthesia (MISGA group), or by laminectomy under general anesthesia (LGA group). All in all, awake surgery appears to show significantly better performance than general anesthesia in terms of patient pain coverage (65% vs. 34–62%), pain surface (50–76% vs. 50–61%) and pain intensity (65% vs. 35–40%), as well as improved secondary outcomes (quality of life, functional disability and depression). One step further, our results suggest that MISAA combined with intra-operative hypnosis could potentialize patient intraoperative cooperation and could be proposed as a personalized package offered to PSPS-T2 patients eligible for SCS implantation in highly dedicated neuromodulation centers.

Keywords